相关临床试验
57
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1997
进行中（未招募）
3
5.3%
已完成
27
47.4%
尚未招募
7
12.3%
招募中
12
21.1%
终止
2
3.5%
Unknown
6
10.5%
暂无批准数据
- A new €15.3 million EU-funded project, ACT-CHIK, will conduct a Phase Ib/III trial of the MV-CHIK chikungunya vaccine across Rwanda, Kenya, Nigeria, and Senegal, enrolling 940 participants including adults, adolescents, and children. - The MV-CHIK vaccine uses a measles virus Schwarz strain vector and has demonstrated satisfactory safety and immunogenicity in six prior Phase I/II trials involving approximately 600 adults. - The four-year initiative will prepare technology transfer of vaccine manufacturing to Institut Pasteur de Dakar, Africa's only WHO-prequalified vaccine manufacturer, supporting the African Union's goal of producing 60% of vaccines locally by 2040. - The international consortium spans seven partners across four continents, coordinated by Institut Pasteur, with the International Vaccine Institute serving as clinical trial sponsor.
- The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded up to $16 million to a Korean consortium led by the International Vaccine Institute to develop the world's first mRNA vaccine against Severe Fever with Thrombocytopenia Syndrome (SFTS). - The project utilizes artificial intelligence and structure-based design to create vaccine candidates using ST Pharm's proprietary SmartCap® and STLNP® platform technologies, marking the first time an SFTS vaccine will be tested in humans. - SFTS, transmitted by ticks in East Asia, causes high fever, thrombocytopenia, and potential multiple organ failure with no current commercial vaccine available. - The research aims to establish a prototype vaccine for the Phenuivirus family that could accelerate development of vaccines against similar emerging viruses within 100 days during future outbreaks.
- TriLink BioTechnologies and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding to collaborate on mRNA-based vaccine development and promote equitable access in low- and middle-income countries. - The partnership combines TriLink's expertise in nucleic acids, including its proprietary CleanCap® technology used in COVID-19 vaccines, with IVI's global health focus on infectious diseases disproportionately affecting developing regions. - This collaboration aims to accelerate vaccine development through knowledge exchange and joint scientific initiatives, potentially transforming access to critical healthcare technologies regardless of geographic location.
